The Distribution of Genotype and Allelic Frequency of IL28B Gene Polymorphism in Andhra Pradesh, India

Journal of Clinical and Experimental Hepatology

Volumn 2, Issue 2, 2012, Pages 112-115

  Sivaprasad, Siddapuram ^a   Rao, Padaki Nagaraja ^b   Gupta, Rajesh ^b   Ashwini, Kaitha ^a   Reddy, Duvvuru Nageshwar ^b  

^a Department of Medical Genetics   (India)

^b ASIAN INSTITUTE OF GASTROENTEROLOGY   (India)

Author keywords

Genotype; Hepatitis C virus; IL28B gene; Single nucleotide polymorphism

Indexed keywords

INTERLEUKIN 28B; PEGINTERFERON; RIBAVIRIN;

ADULT; ALLELE; ANTIVIRAL THERAPY; ARTICLE; CHROMOSOME 19; CONTROLLED STUDY; ETHNIC DIFFERENCE; EVALUATION RESEARCH; FEMALE; GENE; GENE FREQUENCY; GENE LOCATION; GENE SEQUENCE; GENOTYPE; HEPATITIS C; HUMAN; IL28B GENE; INDIA; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; POPULATION DISTRIBUTION; POPULATION GENETICS; PRIORITY JOURNAL; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; VIRAL CLEARANCE;

EID: 84864109586     PISSN: 09736883     EISSN: 22133453     Source Type: Journal    
DOI: 10.1016/S0973-6883(12)60098-X     Document Type: Article

References (26)

1. WHO, World Health Organisation Hepatitis C. Initiative for Vaccine Research [accessed Feb, 2010]. http://www.who.int/vaccine_research/diseases/viralcancers/en/index2.html.
2. Bisceglie AM, Hoofnagle JH Optimal therapy of hepatitis C. Hepatology 2002, 36:S121-S127.
3. David M Signal transduction by type I interferons. Biotechniques 2002, 33:S58-S65.
4. Lindsay KL Introduction to therapy of hepatitis C. Hepatology 2002, 36:S114-S120.
5. Attia J, Ioannidis JP, Thakkinstian A, et al. How to use an article about genetic association: a background concepts. JAMA 2009, 301:74-81.
6. Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009, 461:399-401.
7. Suppiah V, Moldovan M, Ahlenstiel G, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009, 41:1100-1104.
8. Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009, 41:1105-1109.
9. Rauch A, Kutalik Z, Descombes P, et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010, 138:1338-1348.
10. Asselah T Genetic polymorphism and response to treatment in chronic hepatitis C: the future of personalized medicine. J Hepatol 2010, 52:452-454.
11. Christoph S, Simone S, Alexandra D, et al. Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients. J Hepatol 2011, 54:415-421.
12. Conjeevaram HS, Fried MW, Jeffers LJ, et al. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology 2006, 131:470-477.
13. Muir AJ, Bornstein JD, Killenberg PG, et al. Peginterferon Alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-hispanic whites. N Engl J Med 2004, 350:2265-2271.
14. Thomas D, Thio CL, Martin MP, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009, 461:798-801.
15. Miller SA, Dykes DD, Polesky H Simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988, 16:1215.
16. Wohnsland A, Hofmann WP, Sarrazin C Viral determinants of resistance to treatment in patients with hepatitis C. Clin Microbiol Rev 2007, 20:23-38.
17. Kau A, Vermehren J, Sarrazin C Treatment predictors of a sustained virologic response in hepatitis B and C. J Hepatol 2008, 49:634-651.
18. Ghany MG, Strader DB, Thomas DL, Seeff LB Diagnosis, management and treatment of hepatitis C: an update. Hepatology 2009, 49:1335-1374.
19. McCaughan GW, Omata M, Amarapurkar D, et al. Asian Pacific Association for the Study of the Liver consensus statements on the diagnosis, management and treatment of hepatitis C virus infection. J Gastroenterol Hepatol 2007, 22:615-633.
20. Zeuzem S, Berg T, Moeller B, et al. Expert opinion on the treatment of patients with chronic hepatitis C. J Viral Hepatol 2009, 16:75-90.
21. Fried MW Side effects of therapy of hepatitis C and their management. Hepatology 2002, 36:237-244.
22. Yan KK, Marianne G, Thuy D, et al. Treatment responses in Asians and Caucasians with chronic hepatitis C infection. World J Gastroenterol 2008, 14:3416-3420.
23. Liu CH, Liu CJ, Lin CL, et al. Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial. Clin Infect Dis 2008, 47:1260-1269.
24. Wilson JF, Weale ME, Smith AC, et al. Population genetic structure of variable drug response. Nat Genet 2001, 29:265-269.
25. Juan AP, Antonio C, Antonio R, et al. Prediction of response to pegylated interferon plus ribavirin by IL28B gene variation in patients coinfected with HIV and hepatitis C virus. Clin Infect Dis 2010, 51:788-795.
26. Tomokazu K, Nelson HC, Waka O, et al. Predictive value of the IL28B polymorphism on the effect of interferon therapy in chronic hepatitis C patients with genotypes 2a and 2b. J Hepatol 2011, 54:408-414.